Peripheral biological markers and treatment response in schizophrenia

Schizophrenic Psychology: New Research

Volumn , Issue , 2007, Pages 319-370

  Pivac, Nela ^a,b   Muck Seler, Dorotea ^a,b   Mustapic, Maja ^a,b   Sagud, Marina ^a,b   Marcinko, Darko ^a,b   Deẑeljin, Martina ^a,b   Jakovljevic, Miro ^a,b  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b KBC Zagreb   (Croatia)

Author keywords

Biomarkers; Cortisol; Monoamine oxidase; Plasma lipid levels; Platelets; Prolactin; Schizophrenia; Serotonin; Treatment response

Indexed keywords

EID: 63949088292     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (112)

1. Abi-Dargham, A., Laruelle, M., Aghajanian, G.K., Charney, D. and Krystal, J. (1997). The role of serotonin in the pathophysiology and treatment of schizophrenia. Journal of Neuropsychiatry and Clinical Neurosciences, 9, 1-17.
2. Altamura, A.C., Bassetti, R., Cattaneo, E and Vismara S. (2005). Some biological correlates of drug resistance ion schizophrenia: A multidimensional approach. The World Journal of Biological Psychiatry 6(Suppl 2), 23-30.
3. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders. IV Edition. American Psychiatric Press, Washington, DC.
4. 2 receptor binding properties and their regulation by endogenous serotonin. Life Sciences, 52, 313-321.
5. Anderson, G.M., Feibel, F.C., Wetlaufer, L.A., Schlicht, K.R., Ort, S.M. and Cohen, D.J. (1985). Effect of a meal on human whole blood serotonin. Gastroenterology, 88, 86-89.
6. Askenazy, F., Caci, H., Myquel, M., Darcourt, G. and Lecrubier, Y. (2002) Relationship between impulsivity and platelet serotonin content in adolescents, Psychiatry Research 94, 19-28.
7. Balsa, J.A., Sanchez-Franco, F., Pazos, F., Lara, J.I., Lorenzo, M.J., Maldonado, G. and Cacicedo, L. (1998). Direct action of serotonin on prolactin, growth hormone, corticotrophin and luteinizing hormone release in coculture of anterior and posterior pituitary lobes: Autocrine and/or paracrine action of vasoactive intestinal peptide, Neuroendocrinology 68, 326-333.
8. Barisic, I., Pivac, N., Muck-Seler, D., Jakovljevic, M. and Sagud M. (2004). Comorbid depression and platelet serotonin in hemodialysis patients. Nephron Clinical Practice 96, c10-c14.
9. Berlin, I., Said, S., Spreux-Varoquaux, O., Olivares, R., Launay, J.M. and Puech, A.J. (1995). Monoamine oxidase A and B activities in heavy smokers. Biological Psychiatry 38, 756-761.
10. Billett, E.E. (2004). Monoamine Oxidase (MAO) in human peripheral tissues. Neurotoxicology 25, 139-148.
11. Blum, I., Vered, Y., Lifshitz, A., Harel, D., Blum, M., Nordenberg, Y., Harsad, A., Sulkes, J., Gabbay, U. and Graff, E. (1996). The effect of estrogen replacement therapy on plasma serotonin and catecholamines in postmenausal women. Israel Journal of Medical Sciences 32, 1158-1162.
12. Brusov, O.S., Factor, M.I., Zlobina, G.P., Dupin, A.M., Dmitriev, A.D., Lozier, R.H., Beniashvili, A.G. and Morozova, M.A. Platelet 5-HT Content and 5-HT Transporter Immunoreactivity in Schizophrenia: Associations with PANSS-Derived Psychotic Symptoms, The World Journal of Biological Psychiatry (in press).
13. Camacho, A. and Dimsdale, J.E. (2000). Platelets and psychiatry: lessons learned from old and new studies. Psychosomatic Medicine, 62, 326-336.
14. Canuso, C.M., Goldstein, J.M., Wojcik, J., Dawson, R., Brandman, D., Klibanski, A., Schildkraut, J.J. and Green, A.I. (2002). Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorders. Psychiatry Research 111, 11-20.
15. Carroll, B.J., Feinberg, M., Greden, JF., Tarika, J., Albaba, A.A., Haskett, R.F., James, N.M., Kronfol, Z., Lohr, N., Sreiner, M., de Vigne, J.P. and Young, E. (1981) A specific laboratory test for the diagnosis of melancholia: Standardization, validation and clinical utility. Archives of General Psychiatry 38, 15-22.
16. Crawford, A.M.K., Beasley, C.M., Jr. and Tollefson, G.D. (1997). The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Research 26, 41-54.
17. Coccini, T., Randine, G., Castoldi, A.F, Balloni, L., Baiardi, P. and Manzo, L. (2005) Lymphocyte muscarinic receptors and platelet monoamine oxidase-B as biomarkers of CNS function: effects of age and gender in healthy humans, Environmental Toxicology and Pharmacology 19, 715-720.
18. Coirini, H., Kallstrom, L., Wiesel, F.A. and Johnson, A.E. (1997). Modulation of basal ganglia neurotransmission by the classical antipsychotic fluphenazine is due in part to the blockade of dopamine D1- receptors. Molecular Brain Research 49, 197-210.
19. Dinan, T.G. (1996) Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function. Life Sciences 58, 1683-1694.
20. Dossenbach, M.R.K., Folnegovic-Smalc, V., Hotujac, Lj., Uglesic, B., Tollefson, G.D., Grundy, S.L., Friedel, P., Jakovljevic, M., and Olanzapine HGCH Group (2004) Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 28, 311-318.
21. Du Buis, T.M., Deng, C. and Huang, X-F. (2005). Membrane phospholipids composition, alterations in neurotransmitter systems and schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29, 878-888.
22. Duval, F., Mokrani, M-C., Monreal, J., Bailey, P., Valdebenito, M., Crocq, M-A. and Macher, J-P. (2003). Dopamine and serotonin function in untreated schizophrenia: clinical correlates of the apomorphine- and d-fenfluramine tests. Psychoneuroendocrinology 286, 627-642.
23. th Edition. Lippincot Williams and Wilkins, USA, pp. 1129-1147.
24. Engstorm, G., Alling, C., Gustavsson, P., Oreland, L. and Traskman-Bendz, L. (1997). Clinical characteristics and biological parameters in temporal clusters of suicide attempters. Journal of Affective Disorders 44, 45-55.
25. Esel, E., Basturk, M., Gonul, A.S., Kula, M., Turan, T., Yabanogly, I. and Sofuoglu, S. (2001) Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenics patients. Psychoneuroendocrinology 26:641-647.
26. Farren, C.K., Clare, A.W., Tipton, K.F. and Dinan, T.G. (1998). Platelet MAO activity in subtypes of alcoholics and controls in a homogenous population. Journal of Psychiatric Research 32, 49-54.
27. Fowler, J.S., Logan, J., Wang, G.J. and Volkow, N.D. (2003) Monoamine oxidase and cigarette smoking. Neurotoxicology 24: 75-82.
28. Franke, L., Schewe, H.-J., Müller, B., Campman, V., Kitzrow, W., Uebelhack, R., Berghöfer, A. and Müller-Oerlinghausen, B. (2000). Serotonergic platelet variables in unmedicated patients suffering from major depression and healthy subjects. Relationship between 5HT content and 5HT uptake. Life Sciences 47, 301-315.
29. Franke, L., Schewe, H.-J., Uebelhack, R., Berghöfer, A. and Müller-Oerlinghausen, B. (2003). Platelet 5-HT uptake and gastrointestinal symptoms in patients suffering from major depression. Life Sciences 74, 521-531.
30. Fuller Torrey, E.F., Barci, B.M., Webster, M.J., Bartko, J.J., Meador-Woodruff, J.H. and Knable, M.B. (2005) Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biological Psychiatry; online; doi 10.1016/j.biolpsych.2004.10019.
31. Garpenstrand, H., Ekblom, J., Forslund, K., Rylander, G. and Oreland, L. (2000). Platelet monoamine oxidase activity is related to MAOB intron 13 genotype. Journal of Neural Transmission 107, 523-530.
32. Goveas; J.S., Csernansky, J.G., and Coccaro, E.F. (2004) Platelet serotonin content correlates with life history of aggression in personality-disordered subjects. Psychiatry Research 126, 23-32.
33. Govitrapong, P., Mukda, S., Turakitwanakan, W., Dumrongphol, H., Chindaduangratn, C., and Sanvarinda, Y. (2002) Platelet serotonin transporter in schizophrenic patients with and without neuroleptic treatment. Neurochemistry International 41, 209-216.
34. Guicheney, P., Leger, D., Barrat, J., Trevoux, R., De Lignieres, B., Roques, P., Garnier, J.P., Boyers, P., Grenier, J., Dreux, C. and Meyer, P. (1988). Platelet serotonin content and plasma tryptophan in peri- and postmenopausal women: variations with plasma oestrogen levels and depressive symptoms. European Journal of Clinical Investigation 18, 297-304.
35. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976.
36. Halbreich, U., Kinon, B.J., Gilmore, J.A. and Kahn, L.S. (2003) Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 28, 53-67.
37. Hallman, J., Oreland, L., Edman, G. and Schalling, D. (1987). Thrombocyte monoamine oxidase activity and presonality traits in women with severe premenstrual syndrome. Acta Psychiatrica Scandinavica 76: 225-234.
38. Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 56-62.
39. Huang, T.L. and Chen, J.F. (2005). Serum lipid profiles and schizophrenia: Effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophrenia Research doi: 10:1016/jschres.2005.05.001.
40. Huerta, R., Mena, A., Malacaara, J.M. and de León, J.D., (1995). Symptoms of the menopausal and premenopausal years: their relationship with insulin, glucose, cortisol, FSH, prolactin, obesity and attitudes towards sexuality. Psychoneuroendocrinology 20, 851-864.
41. Iqbal, N. and van Praag, H.M. (1995). The role of serotonin in schizophrenia. European Neuropsychopharmacology 5, Suppl S, 11-23.
42. Jakovljevic, M., Muck-Seler, D., Pivac, N., Ljubicic, Đ., Bujas, M. and Dodig, G., (1997). Seasonal influence on platelet 5-HT concentrations in patients with recurrent major depression and schizophrenia. Biological Psychiatry 41, 1028-1034.
43. Jakovljevic, M., Muck-Seler, D., Pivac, N. and Željka Crnčević (1998). Platelet 5-HT and plasma cortisol concentrations after dexamethasone suppression test in patients with different time course of schizophrenia. Neuropsychobiology, 37, 142-145.
44. Kane, J., Honigfeld, G., Singer, J., Meltzer, H. and The Clozaril Collaborative Study Group. (1988). Clozapine for the treatment-resistant schizophrenics: a double-blind comparison versus chlorpromazine/benztropine. Archives in General Psychiatry 45, 789-796.
45. Karolewitz, B., Klimek, V., Zhu, H., Szebeni, K., Nail, E., Stockmeier, C.A., Johnson, L. and Ordway, G.A. (2005) Effects of depression, cigarette smoking, and age on monoamine oxidase B in amygdaloid nuclei. Brain Research 1043, 57-64.
46. Kelly, B.D. (2005) Structural violence and schizophrenia. Social Science and Medicine 61, 721-730.
47. Kozaric-Kovacic, D., Ljubin, T., Rutic-Puz, L., Mihaljevic, J., Jernej, B., and Cicin-Sajn, L. (2000) Platelet monoamine oxidase activity, ego strength, and neuroticism in soldiers with combat related current posttraumatic stress disorder. Croatian Medical Journal 41, 76-80.
48. Krajl, M. (1965). A rapid microfluorimetric determination of monoamine oxidase. Biochemical Pharmacology 14, 1683-1685.
49. Kugaya, A., Sanacora, G., Staley, J.K., Malison, R.T., Bozkurt, A., Khan, S., Anand, A., van Dyck, C.H., Baldwin, R.M., Seibyl, J.P., Charney, D., and Innis, R.B. (2004). Brain serotronin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biological Psychiatry 56, 497-502.
50. Kumar, A.D., Weiss, S., Fernandez, J.B., Cruess, D. and Eisdorfer, C. (1998). Peripheral serotonin levels in women: role of aging and ethnicity. Gerontology 44, 211-216.
51. Lee, M.A. and Meltzer, H.Y. (2001). 5-HT1A receptor dysfunction in female patients with schizophrenia. Biological Psychiatry 50, 758-766.
52. Leibenluft, E., Fiero, P.L. and, David, R. (1994). Effects of menstrual cycle on dependent variables in mood disorder research. Archives in General Psychiatry 51, 761-781.
53. Lesch, K.P., Baling, U., Gross, J., Strauss, K., Wolozin, B., Murphy, D.L. and Riederer, P. (1994). Organization of the human serotonin transporter gene. Journal of Neuronal Transmission 95, 157-162.
54. Longato-Stadler, E., Klinteberg, B., Garpenstrand, H., Oreland, L. and Hallman, J. (2002). Personality traits and platelet monoamine oxidase activity in a Swedish male criminal population. Neuropsychobiology 46, 202-208.
55. Lowry, O.H., Rosenbrough, N.S., Farr, A.C. and Randall, R.J. (1951). Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 193, 265-75.
56. Lucki, I. (1998). The spectrum of behaviors influenced by serotonin. Biological Psychiatry 44, 151-162.
57. Marčinko, D., Martinac, M., Karlović, D., Filipčić, I., Lončar, C., Pivac, N. and Jakovljević, M. (2005). Are there differences in serum cholesterol and cortisol concentrations between violent and non-violent schizophrenic male suicide attempters? Collegium Antropologicum 29: 153-157.
58. Mattson, M. P., Maudsley, S. and Martin, B. (2004) BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends in Neurosciences 27, 589-594.
59. Meltzer, H.Y. and Maes, M., (1994). Effect of pindolol on the L-5-HTP-induced increase in plasma prolactin and cortisol concentrations in man. Psychopharmacology 114, 635-643.
60. Meltzer, H.Y. and Nash, J.F. (1991). VII: Effects of antipsychotic drugs on serotonin receptors. Pharmacolological Reviews 43, 587-604.
61. Mendelson, S.C. (2000). The current status of the platelet 5-HT2A receptor in depression. Journal of Affective Disorders 57, 13-24.
62. Mimica, N., Muck-Seler, D, Pivac, N., Mustapic, M. and Folnegovic-Smalc, V. (2004) Platelet serotonin and monoamine oxidase activity in patients with early-onset and late-onset of Alzheimer's disease. Periodicum Biologorum 107, 211-215.
63. Muck-Seler, D., Jakovljevic, M., and Deanovic, Z. (1988). Time course of schizophrenia and platelet 5-HT level. Biological Psychiatry 23, 243-251.
64. Muck-Seler, D., Jakovljevic, M. and Deanovic, Z. (1991). Platelet serotonin in subtypes of schizophrenia and unipolar depression. Psychiatry Research 38, 105-113.
65. Muck-Seler, D., Jakovljevic, M. and Pivac, N. (1996a). Platelet 5-HT concentrations and suicidal behavior in recurrent major depression. Journal of Affective Disorders 39, 73-80.
66. Muck-Seler, D., Bujas, M., Ljubić-Thibal, V., and Jakovljevic, M. (1996b). Effect of age on platelet 5-HT concentrations in healthy controls, depressed and schizophrenic patients. Neuropsychobiology 36, 19-21.
67. Muck-Seler, D., Pivac, N., Jakovljević, M. and Brzović, Z (1999a) Platelet 5-HT, plasma cortisol and dexamethasone suppression test in schizophrenic patients. Biological Psychiatry, 45, 1433-1439.
68. Muck-Seler, D., Pivac, N., and Jakovljević, M. (1999b). Sex differences, season of birth and platelet 5-HT levels in schizophrenic patients. Journal of Neural Transmission 106:337-347.
69. Muck-Seler, D., Pivac, N., Sagud, M., Jakovljevic, M. and Mihaljević-Peleš, A. (2002). The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 26, 1235-1243.
70. Muck-Šeler, D., Pivac, N., Jakovljević, M., Šagud, M. and Mihaljević-Peleš, A. (2003). Platelet 5-HT concentration and comorbid depression in war veterans with or without posttraumatic stress disorder. Journal of Affective Disorders 75, 171-179.
71. Muck-Seler, D., Pivac, N., Mustapic, M., Crncevic, Z., Jakovljevic, M. and Sagud, M. (2004). Platelet serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women. Psychiatry Research 127, 217-226.
72. Muck-Seler, D., Pivac, N., Sagud, M., Mustapic, M and Jakovljevic, M. (2005). The effects of serotonin uptake inhibitors on platelet serotonin: From basic to clinical studies. Trends in serotonin uptake inhibitors research, (Shirley, A.C, editor), NOVA Science Publishers, Inc, NY, Hauppauge, USA, in press.
73. Muller-Oerlinghausen, B., Roggenbach, J. and Franke, L. (2004) Serotonergic platelet markers of suicidal behavior - do they really exist? Journal of Affective Disorders 79, 13-24.
74. Nicotra, A., Pierucci, F., Parvez, H. and Senatori, O. (2004). Monoamine oxidase expression during development and aging. Neurotoxicology 25(1-2), 155-165.
75. Nishizawa, S., Benkelfat, C., Young, S.N., Leyton, M., Mzengeza, S., De Montigny, C., Blier, P., and Diksic, M. (1997). Differences between males and females in rates of serotonin synthesis in human brain. Proceedings of the National Academy of Sciences of USA 94, 5308-5313.
76. Oreland, L. and Shaskan, E.G. (1983) Monoamine oxidase activity as a biological marker. Trends in Pharmacological Sciences 4, 339-341.
77. Oreland, L., Damberg, M., Hallman, J. and Garpenstrand, H. (2002) Smoking only explains part of the associations between platelet monoamine oxidase activity and personality. Journal of Neural Transmission 109, 963-975.
78. Oreland, L. (2004). Platelet monoamine oxidase, personality and alcoholism: The rise, fall and resurrection. Neurotoxicology 25, 79-89.
79. Oxenkrug, G.F. (1979). The content and uptake of 5-HT by blood platelets in depressive patients. Journal of Neural Transmission 45, 285-289.
80. Pavlova, E.V., Brusov, O.S., Factor, M.I., Dmitriev, A.D. and Morozova, M.A. (2005). Psychosis in schizophrenia: Link with platelet 5-HT markers. The World Journal of Biological Psychiatry, 6(Suppl 1), 233.
81. Pivac, N., Jakovljevic, M., Muck-Seler, D., and Brzović, Z. (1997a). Hypothalamic-pituitary-adrenal axis function and platelet serotonin concentrations in depressed patients. Psychiatry Research 73, 123-132.
82. Pivac, N., Muck-Seler, D. and Jakovljević, M. (1997b) Platelet 5-HT levels and hypothalamic-pituitary-adrenal axis activity in schizophrenic patients with positive and negative symptoms. Neuropsychobiology, 36, 19-21.
83. Pivac, N., Mück-Šeler, D., Barišić, I., Jakovljević, M., and Puretić, Z. (2001) Platelet serotonin concentration in dialysis patients with somatic symptoms of depression. Life Sciences 68, 2423-2433.
84. Pivac, N., Muck-Seler, D., Sagud, M. and Jakovljevic, M. (2002). Platelet serotonergic markers in posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 26(6), 1193-1198.
85. Pivac, N., Muck-Seler, D., Šagud, M., Jakovljevic, M., Mustapić, M., and Mihaljević-Peleš, A. (2003). Long-term sertraline treatment and peripheral biochemical markers in female depressed patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry 27, 759-765.
86. Pivac, N., Muck-Seler, D., Mustapic, M., Nenadic-Sviglin, K. and Kozaric-Kovacic, D. (2004) Platelet serotonin concentration in alcoholic subjects. Life Sciences, 76:521-531.
87. Pivac, N., Muck-Seler, D., Kozaric-Kovacic, D., Mustapic, M., Nenadic-Sviglin, K. and Deželjin M (2005) Platelet monoamine oxidase in alcoholism. Psychopharmacology, DOI 10.1007/s00213-005-0045-0.
88. Rasgon, N., McGuire, M., Tanavoli, S., Fairbanks, L. and Rapkin, A. (2000) Neuroendocrine response to an intravenous L-tryptophan challenge in women with premenstrual syndrome. Fertility and Sterility, 73 144-149.
89. Richelson, E., and Souder, T. (2000). Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sciences 68, 29-39.
90. 11C]-methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. Archives of General Psychiatry 61, 556-563.
91. Ryan, M.C.M., Collins, P. and Thakore, J.H. (2003). Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. American Journal of Psychiatry 160, 284-289.
92. Ryan, M.C.M., Sharifi, N., Condren, R. and Thakore, J.H. (2004). Evidence of basal pituitary-adrenal overactivity in first episode, drug naïve patients with schizophrenia. Psychoneuroendocrinology 29, 1065-1070.
93. Saari, K., Jokelainen, J., Veijola, J., Koponen, H., Jones, P.B., Savolainen, M., Järvelin, M.-R., Lauren, L., Isohanni, M. and Lindeman, S. (2004). Serum lipids in schizophrenia and other functional psychoses: a general population northern Finland 1966 birth cohort survey. Acta Psychiatrica Scandinavica 110, 279-285.
94. Sagud, M., Pivac, N., Mück-Šeler, D., Jakovljević, M., Mihaljević-Peleš, A. and Koršić, M. (2002). Effects of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients. Neuropsychobiology 45, 139-143.
95. Schalling, D., Asberg, M., Edman, G. and, Oreland, L., (1987). Markers for vulnerability to psychopathology: Temperament traits associated with platelet MAO activity. Acta Psychiatrica Scandinavica 76(2), 172-182.
96. Schmidt, P.J., Raju, J., Danaceau, M., Murphy, D.L. and Berlin, R.E. (2002) The effects of gender and gonadal steroids on the neuroendocrine and temperature response to m-chlorophenylpiperazine in leuprolide-induced hypogonadism in women and men. Neuropsychopharmacology 27, 800-812.
97. Schwartz, P.J., Turner, E.H., Garcia-Borreguero, D., Sedway, J., Vetticad R.G., Wehr, T.A., Murphy, D.L. and Rosenthal, N.E., (1999). Serotonin hypothesis of winter depression: behavioral and neuroendocrine effects on the 5-HT1A receptor partial agonist ipsapirone in patients with seasonal affective disorder and healthy control subjects. Psychiatry Research 86, 9-28.
98. Snell, L.D., Glanz, J. and Tabakoff, B. (2002). Relationship between effects of smoking, gender, and alcohol dependence on platelet monoamine oxidase-B activity, affinity labeling, and protein measurements. Alcoholism: Clinical and Experimental Research 26(7), 1105-1113.
99. Stahl, S.M. (1985). Platelets as pharmacological models for the receptors and biochemistry of monoaminergic neurons. In: Longenecker GL, (Ed.), Platelets: Physiology and Pharmacology, Academic Press, New York, 1985; 307-340.
100. Stahl, S.M. (1998). Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. Journal of Affective Disorders 51, 215-35.
101. Tandon, R., Mazzara, C., DeQuardo, J., Craig, K.A., Meador-Woodruff, J.H., Goldman, R. and Greden, J.F. (1991) Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome. Biological Psychiatry 29, 953-964.
102. Tandon, R. and Jibson, M.D. (2003) Efficacy of newer generation of antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28, 9-26.
103. Tandon, R. and Halbreich, U. (2003) The second-generation "atpical"antipsychotics: similar improved efficacy but different neuroendocrine side effects. Psychoneuroendocrinology 28, 1-7.
104. Van Amelsvoort, T.A.M.J., Abel, K.M., Robertson, D.M.R., Daly, E., Critchley, H., Withehead, M. and Murphy, D.G.M. (2001) Prolactin response to d-fenfluramine in postmenopausal women on and off ERT: comparison with young women. Psychoneuroendocrinology 26, 493-502.
105. Van Heeringen, K., Audenaert, K., Van de Wiele, L. and Verstraete, A. (2000) Cortisol in violent suicidal behavior: association between personality and monoaminergic activity. Journal of Affective Disorders 60, 181-189.
106. Van der Heijden, F.M-M-A., Tuinier, S., Fekkes, D., Sijben, A.E.S., Kahn, R.S. and Verhoeven, W.M.A. (2004) Atypical antipsychotics and the relevance of glutamate and serotonin. European Neuropsychopharmacology 14, 259-265.
107. Veral A, Alper G, Mentes G, Ersoz B (1997) Age and sex related alterations in serum and platelet monoamine oxidase: European Journal of Clinical Chemistry and Clinical Biochemistry 35: 265-268.
108. 3H] paroxetine binding related to impulsive suicide attempts and borderline personality disorder. Biological Psychiatry 43(10), 740-746.
109. Warner, M.D., Walker, A.M., D'Souza, D.C., Lee, D., Nasseri, D. and Peabody, C.A., (2001). Lower prolactin bioactivity in unmedicated schizophrenic patients. Psychiatry Research 102, 249-254.
110. Wirtz-Justice, A., Lichtsteiner, M. and Feer, H. (1977). Diurnal and seasonal variations in human platelet serotonin in man. Journal of Neuronal Transmission 42, 7-15.
111. Wistedt, B., Willes, D. and Kolakowska, T. (1981) Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics. Lancet 1(8239), 1163.
112. Wong, A.H.C. and Van Tol, H.H.M. (2003) Schizophrenia: from phenomenology to neurobiology. Neuroscience and Biobehavioral Reviews, 27, 269-306.